Venker Eric's most recent trade in Roivant Sciences Ltd was a trade of 200,000 Common Shares done at an average price of $3.9 . Disclosure was reported to the exchange on Jan. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 12 Jan 2026 | 200,000 | 1,854,597 | - | 3.9 | 770,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 12 Jan 2026 | 200,000 | 1,654,597 | - | 21.9 | 4,384,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 200,000 | 5,244,834 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 23 Dec 2025 | 313,841 | 1,811,749 | - | 3.9 | 1,208,288 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2025 | 313,841 | 5,562,682 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 22.45 per share. | 23 Dec 2025 | 200,000 | 1,611,749 | - | 22.5 | 4,490,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 23 Dec 2025 | 117,848 | 1,729,597 | - | 3.9 | 453,715 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2025 | 117,848 | 5,444,834 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 22.53 per share. | 23 Dec 2025 | 75,000 | 1,654,597 | - | 22.5 | 1,689,750 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 200,000 | 5,876,523 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 20.85 per share. | 09 Dec 2025 | 200,000 | 1,497,908 | - | 20.9 | 4,170,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 09 Dec 2025 | 200,000 | 1,697,908 | - | 3.9 | 770,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.27 per share. | 20 Nov 2025 | 7,051 | 1,497,908 | - | 20.3 | 142,924 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 200,000 | 6,076,523 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 07 Nov 2025 | 200,000 | 1,704,959 | - | 3.9 | 770,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 07 Nov 2025 | 200,000 | 1,504,959 | - | 20.2 | 4,044,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 15 Oct 2025 | 414,683 | 1,919,642 | - | 15.9 | 6,572,726 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 414,683 | 436,700 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 15 Oct 2025 | 414,683 | 1,504,959 | - | 16.9 | 7,020,583 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 318,282 | 118,418 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 17.05 per share. | 15 Oct 2025 | 318,282 | 1,504,959 | - | 17.0 | 5,426,708 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 15 Oct 2025 | 318,282 | 1,823,241 | - | 15.9 | 5,044,770 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 15 Oct 2025 | 118,418 | 1,504,959 | - | 17.1 | 2,020,211 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 118,418 | 0 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 15 Oct 2025 | 118,418 | 1,623,377 | - | 15.8 | 1,876,925 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 09 Oct 2025 | 104,940 | 1,609,899 | - | 15.9 | 1,663,299 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 104,940 | 872,110 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 16.30 per share. | 09 Oct 2025 | 104,940 | 1,504,959 | - | 16.3 | 1,710,522 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 20,727 | 851,383 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 16.25 per share. | 09 Oct 2025 | 20,727 | 1,504,959 | - | 16.3 | 336,814 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 09 Oct 2025 | 20,727 | 1,525,686 | - | 15.9 | 328,523 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 06 Oct 2025 | 355,161 | 1,504,959 | - | 16.1 | 5,735,850 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 180,859 | 6,276,523 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 06 Oct 2025 | 180,859 | 1,860,120 | - | 3.8 | 696,307 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 16.34 per share. | 06 Oct 2025 | 171,396 | 1,504,959 | - | 16.3 | 2,800,611 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 16.20 per share. | 06 Oct 2025 | 138,602 | 1,504,959 | - | 16.2 | 2,245,352 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 128,295 | 0 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. | 06 Oct 2025 | 128,295 | 1,643,561 | - | 7.5 | 955,798 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 06 Oct 2025 | 127,355 | 1,632,314 | - | 15.9 | 2,018,577 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 127,355 | 1,054,528 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 107,131 | 128,295 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. | 06 Oct 2025 | 107,131 | 1,679,261 | - | 7.5 | 798,126 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 67,171 | 987,357 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 06 Oct 2025 | 67,171 | 1,572,130 | - | 15.8 | 1,064,660 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 24,900 | 235,426 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. | 06 Oct 2025 | 24,900 | 1,657,214 | - | 7.5 | 185,505 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 19,141 | 6,457,382 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 06 Oct 2025 | 19,141 | 1,676,355 | - | 3.9 | 73,693 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 10,307 | 977,050 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. | 06 Oct 2025 | 10,307 | 1,515,266 | - | 15.9 | 163,366 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2025 | 1,000,000 | 7,038,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 19 Sep 2025 | 1,000,000 | 2,653,585 | - | 3.9 | 3,850,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 14.95 per share. | 19 Sep 2025 | 683,818 | 1,969,767 | - | 14.9 | 10,223,079 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 19 Sep 2025 | 611,000 | 1,504,959 | - | 14.8 | 9,061,130 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2025 | 462,374 | 6,576,523 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 19 Sep 2025 | 462,374 | 2,432,141 | - | 3.9 | 1,780,140 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 14.99 per share. | 19 Sep 2025 | 316,182 | 2,215,959 | - | 15.0 | 4,739,568 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2025 | 100,000 | 6,476,523 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 19 Sep 2025 | 100,000 | 2,115,959 | - | 15.0 | 1,501,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 19 Sep 2025 | 100,000 | 2,532,141 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2025 | 100,000 | 8,038,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 11.72 per share. | 20 Aug 2025 | 100,000 | 1,653,585 | - | 11.7 | 1,172,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Aug 2025 | 100,000 | 1,753,585 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.72 per share. | 20 Aug 2025 | 7,051 | 1,653,585 | - | 11.7 | 82,638 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 198,413 | 1,660,636 | - | 0 | Common Shares | |
| Immunovant Inc | Eric Venker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 1,475,000 | 1,475,000 | - | - | Capped Value Appreciation Rights | |
| Immunovant Inc | Eric Venker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 1,300,000 | 1,300,000 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Eric Venker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 189,900 | 189,900 | - | - | Stock Option (right to buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2025 | 100,000 | 8,138,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 21 Jul 2025 | 100,000 | 1,462,223 | - | 11.5 | 1,152,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 21 Jul 2025 | 100,000 | 1,562,223 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 100,000 | 8,238,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Jun 2025 | 100,000 | 1,562,223 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.45 per share. | 20 Jun 2025 | 100,000 | 1,462,223 | - | 11.5 | 1,145,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 785,026 | 8,338,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 02 Jun 2025 | 785,026 | 2,028,501 | - | 3.8 | 3,022,350 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 600,000 | 9,123,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 02 Jun 2025 | 600,000 | 1,677,197 | - | 3.9 | 2,310,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 02 Jun 2025 | 566,278 | 1,462,223 | - | 11.2 | 6,353,639 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.07 per share. | 02 Jun 2025 | 433,722 | 1,243,475 | - | 11.1 | 4,801,303 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 100,000 | 9,723,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 20 May 2025 | 100,000 | 1,077,197 | - | 11.0 | 1,095,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 May 2025 | 100,000 | 1,177,197 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. | 20 May 2025 | 39,148 | 1,077,197 | - | 11.0 | 432,194 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.22 per share. | 20 Apr 2025 | 100,000 | 1,116,345 | - | 10.2 | 1,022,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2025 | 100,000 | 9,823,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Apr 2025 | 100,000 | 1,216,345 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. | 20 Apr 2025 | 10,945 | 1,116,345 | - | 10.2 | 111,092 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 602,311 | 9,923,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Mar 2025 | 602,311 | 1,561,768 | - | 3.8 | 2,318,897 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.82 per share. | 20 Mar 2025 | 434,478 | 1,127,290 | - | 10.8 | 4,701,052 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 400,000 | 10,526,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Mar 2025 | 400,000 | 1,274,979 | - | 3.9 | 1,540,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.06 per share. | 20 Mar 2025 | 315,522 | 959,457 | - | 11.1 | 3,489,673 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. | 20 Mar 2025 | 10,945 | 874,979 | - | 11.0 | 120,067 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Feb 2025 | 100,000 | 996,869 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2025 | 100,000 | 10,926,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 20 Feb 2025 | 100,000 | 896,869 | - | 10.7 | 1,065,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.72 per share. | 20 Feb 2025 | 10,945 | 885,924 | - | 10.7 | 117,330 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 300,000 | 11,026,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 300,000 | 11,326,234 | - | - | Stock Option (Right to Buy) |